Source link : https://www.newshealth.biz/health-news/novel-agent-for-chronic-gvhd-wins-fda-approval/
The FDA approved the colony stimulating factor-1 receptor (CSF-1R) inhibitor axatilimab (Niktimvo) for chronic graft-versus-host-disease (cGVHD) that has failed two prior lines of systemic therapy. The approval allows use in adults and pediatric patients weighing at least 40 kg. Incyte received the biologics license for the monoclonal antibody. Support for approval came primarily from the […]
Author : News Health
Publish date : 2024-08-14 21:34:04
Copyright for syndicated content belongs to the linked Source.
Categories